 Natco Challenges Celgene's Revlimid
9/6/2010 8:34:01 AM
[Zacks] - Celgene Corporation's complaint alleging patent infringement against Natco Pharma.
|
Next Week's Guest: Burton Malkiel
9/6/2010 5:00:00 AM
|
Exelixis Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
9/3/2010 7:00:00 PM
[Business Wire] - SOUTH SAN FRANCISCO, Calif.----Exelixis, Inc. announced that today it granted restricted stock units representing an aggregate of 25,200 shares of Exelixis common stock to nine new employees.
|
Curis to Present at the Rodman & Renshaw 12th Annual Healthcare Conference
9/3/2010 3:05:00 PM
[Business Wire] - CAMBRIDGE, Mass.----Curis, Inc. , a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the company will be presenting at the Rodman & Renshaw 12th Annual Healthcare Conference at 10:50 a.m.
|
Genzyme's Termeer Could Sell Company
9/3/2010 11:40:44 AM
|
The Zacks Small-Cap Profile include: Transdel Pharmaceuticals
9/3/2010 8:51:40 AM
[Zacks] - The Zacks Small-Cap Profile include: Transdel Pharmaceuticals
|
Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
9/3/2010 8:30:00 AM
[PR Newswire] - Regeneron Pharmaceuticals, Inc. will webcast its presentation at the Morgan Stanley Global Healthcare Conference on Monday, September 13, 2010. The presentation is scheduled for 1:00 p.m.
|
Celgene's Revlimid patents challenged by Natco
9/3/2010 7:43:08 AM
[AP] - Celgene Corp. said Friday that Natco Pharma Ltd. is challenging the biotechnology company's patents on the cancer drug Revlimid and it plans to defend them.
|
